Yongkun Sun
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Cancer Institute and Hospital, Chinese Academy of Medical SciencesCancer · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yongkun Sun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07724223 · Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCCancer Institute and Hospital, Chinese Academy of Medical Sciences · recruiting · Metastatic Colorectal Cancer (CRC) · principal investigator
- Ph2NCT06543069 · Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences · recruiting · Malignant Peritoneal Mesothelioma, Advanced · study chair
- Ph2NCT06490107 · Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTCCancer Institute and Hospital, Chinese Academy of Medical Sciences · active not recruiting · Biliary Tract Cancer · study chair
- Ph2NCT06403709 · Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC PatientsCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Metastatic Colorectal Cancer · study chair
- Ph1/Ph2NCT06202001 · Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC PatientsCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Metastatic Colorectal Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:13 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- 150 citationsRCR 11.7
- Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).J Clin Oncol · 2024124 citationsRCR 13.8
- Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.J Clin Oncol · 2013114 citationsRCR 2.6
- Effect of Baduanjin Qigong Exercise on Cancer-Related Fatigue in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial.Oncol Res Treat · 201994 citationsRCR 5.3
- 83 citationsRCR 4.8
- 80 citationsRCR 7.7
- Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.Signal Transduct Target Ther · 202479 citationsRCR 8.7
- Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study.Clin Epigenetics · 202068 citationsRCR 3.2
- Laparoscopic versus conventional open resection of rectal carcinoma: A clinical comparative study.World J Gastroenterol · 200453 citationsRCR 1.9
- Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).Oncologist · 202153 citationsRCR 2.4